Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000004
Chunk: 3

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 3
---
 The full year management guidance for the fiscal year ending March 31, 2025 (FY2024) has been revised from the previous management guidance announced on October 31, 2024, as follows:

CER % Change

|                       |     | Previous Management Guidance 
 (October 31, 2024)           |     | Revised Management Guidance 
 (January 30, 2025)          |
|:----------------------|:----|:-----------------------------|:----|:----------------------------|
| Core Revenue          |     | Flat to slightly increasing  |     | Low-single-digit % increase |
| Core Operating Profit |     | Mid-single-digit % decline   |     | Low-single-digit % increase |
| Core EPS              |     | Approx 10% decline           |     | Flat to slightly declining  |

#### About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

#### Contacts
| Investor Relations             
 Christopher O’Reilly           
 christopher.oreilly@takeda.com 
 +81 (0) 3-3278-2543            |     | Media Relations                
 Brendan Jennings               
 brendan.jennings@takeda.com    
 +81 (0) 80-2705-8259           
 (Outside Japan business hours) 
 Media_relations@takeda.com     |

#### Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or